Active pharmaceutical ingredient manufacturer Savior Lifetec Corp (展旺生技) yesterday said its plant in Europe had secured a good manufacturing practice (GMP) certificate from a regulatory agency in France to sell its sterile injections in the continent.
“Entering Europe’s injection market is an important milestone for the company,” an official at Savior Lifetec, who declined to be named, said by telephone.
Production of sterile injections at the new plant is expected to start contributing to the company’s revenue in September, she said, without providing exact figures.
The new plant is capable of manufacturing 1 million units of injections per month. It will produce injections for antibiotics, such as Meropenem, Imipenem and Ertapenem, which are generic drugs used to treat many types of infections, she said.
The official said the company would sell the products to European clients on a contract basis, without elaborating.
Savior Lifetec reported losses of NT$452.83 million (US$15.1 million) last year, up from losses of NT$234.56 million a year ago because of increasing research and development expenditure, while revenue rose 6.5 percent to NT$837.82 million year-on-year.
Revenue from January through last month increased 64.98 percent to NT$204.71 million from a year ago, according to the company’s filing to Taiwan Stock Exchange.
“We are likely to report losses this quarter, but we may swing back into black this year because of cost reduction and licensed applications,” she said.